Harrow's Vevye (Cyclosporine Ophthalmic Solution) 0.1%, A Patented, Non‑Preserved, Twice-daily Dosed Prescription Drug Based On A "Water‑Free" Semifluorinated Alkane Eyedrop Technology, Is Now Available In The U.S. And Includes A 100% Money‑Back Guarantee
Portfolio Pulse from Benzinga Newsdesk
Harrow Health, Inc. has announced the availability of Vevye, a patented cyclosporine ophthalmic solution for treating dry eye disease (DED) in the U.S. Vevye is unique for its 'water-free' semifulorinated alkane technology and is dispensed in a 10 microliter drop. It is the first cyclosporine-based product to treat both signs and symptoms of DED and comes with a 100% money-back guarantee.
January 11, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Harrow Health's launch of Vevye could potentially increase its market share in the DED treatment sector, offering a unique product with a money-back guarantee.
The introduction of Vevye by Harrow Health represents a significant product launch in the DED treatment market. The unique features of the product, such as the 'water-free' technology and the 100% money-back guarantee, could differentiate it from competitors and potentially lead to increased sales and market penetration. This positive development is likely to be viewed favorably by investors, potentially leading to a short-term increase in Harrow Health's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100